Spyre Therapeutics, Inc. (NasdaqGS: SYRE)
Health Care · Biotechnology · US
$85.66
-0.04% today · +353.0% 1Y
Spyre Therapeutics, Inc. (NasdaqGS: SYRE) operates in the Biotechnology industry within the Health Care sector. The company is valued at $8.01B and employs 125 people.
Over the last twelve months the share price has gained 353.0%, trading between 18.12 and 110.18.
Tweenvest scores Spyre Therapeutics, Inc. across four factors: quality 37/100, value 90/100. Its strongest factor is value.
SYRE price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $8.01B
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -2.01
- Dividend yield
- —
- Beta (5Y)
- 3.11
- 52-week high
- $110.18
- 52-week low
- $18.12
- Avg volume (3M)
- —
- Shares outstanding
- 93.45M
- Employees
- 125
- Next earnings
- —
About Spyre Therapeutics, Inc.
Spyre Therapeutics, Inc. is a biotechnology firm operating at the preclinical stage, dedicated to creating innovative treatments for individuals afflicted with inflammatory bowel disease (IBD). Among its pipeline candidates is SPY001, a human monoclonal immunoglobulin G1 antibody specifically engineered to target and bind with the a4ß7 integrin. This particular therapy is under development for addressing both ulcerative colitis and Crohn's disease, two forms of IBD. Furthermore, Spyre Therapeutics is advancing SPY002, another human monoclonal antibody that aims to interact with tumor necrosis factor-like ligand 1A (TL1A). A synergistic approach is also being explored with SPY120, a compound that merges the anti-a4ß7 action of SPY001 with the anti-TL1A activity of SPY002. All these programs are currently undergoing preclinical evaluation. Beyond these, the company's early-stage portfolio encompasses several additional promising candidates: SPY003, an anti-IL-23 monoclonal antibody; SPY004, a monoclonal antibody with a novel mechanism of action; SPY130, which combines anti-a4ß7 and anti-IL-23 antibodies; and SPY230, a dual antibody therapy featuring anti-TL1A and anti-IL-23 components. Originally incorporated in 2013, the organization was previously known as Aeglea BioTherapeutics, Inc., before rebranding to Spyre Therapeutics, Inc. in November 2023. Its headquarters are located in Waltham, Massachusetts.
- ISIN
- US00773J2024
- Founded
- 2013
- Listed since
- Apr 7, 2016
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Protagonist Therapeutics, Inc.NasdaqGM: PTGX | $9.30B | $144.79 | +0.74% |
| Arrowhead Pharmaceuticals, Inc.NasdaqGS: ARWR | $8.86B | $60.85 | -3.04% |
| Cytokinetics, IncorporatedNasdaqGS: CYTK | $8.75B | $63.06 | +0.24% |
| Caris Life Sciences, Inc.NasdaqGS: CAI | $8.39B | $29.02 | -2.29% |
| TG Therapeutics, Inc.NasdaqCM: TGTX | $7.85B | $55.67 | +0.54% |
| ABIVAX Société AnonymeENXTPA: ABVX | $7.71B | €79.00 | +2.46% |
| RemeGen Co., Ltd.SEHK: 9995 | $7.56B | HK$70.40 | -3.43% |
| Ionis Pharmaceuticals, Inc.NasdaqGS: IONS | $7.52B | $44.13 | -2.54% |
Figures last refreshed Oct 11, 2026.